Thetis Pharmaceuticals Announces Patent Issuance in China for First-in-Class Resolvin E1 Drug
Patent expands coverage to the world’s 2nd largest pharmaceutical market after the U.S.
Essex, CT – (June 15, 2022) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a small molecule ChemR23 agonist to treat cancer and chronic inflammatory diseases, announced that the China National Intellectual Property Administration has granted patent CN 109562186 providing composition of matter protection for TP-317.
“TP-317 is a novel small molecule that represents a highly differentiated approach to regulating immune homeostasis with broad therapeutic potential in cancer and autoimmune diseases,” said Gary Mathias, co-founder and CEO of Thetis. “With long-term patents issued in the U.S., Europe, Japan and now China, TP-317 has the intellectual property foundation to support clinical development in all major markets.”
About Thetis Pharmaceuticals
Overview: TP-317 is a patented small molecule drug that delivers Resolvin E1, an endogenous lipid mediator that engages BLT1 as a biased agonist to promote immune homeostasis . Unlike anti-inflammatory drugs and anti-cancer agents that are immuno-suppressive, TP-317 activates innate and adaptive immune pathways to treat disease without compromising host-protective immunity.
IBD Program: TP-317 is being developed in IBD as first-line, oral therapy for moderate-to-severe Crohn’s disease and as second-line, oral therapy for moderate-to-severe ulcerative colitis in patients who are not well controlled on existing therapies. The anticipated high safety premium and unique epithelial repair mechanism of TP-317 supports its use as adjunct therapy to standard-of-care biologics and oral immunomodulators.
Cancer Program: TP-317 is being developed in cancer as an adjunct to standard of care therapy in advanced colorectal cancer and advanced non-small-cell lung cancer (NSCLC). Its unique myeloid-directed antigen presentation mechanism of action addresses a fundamental need in immunotherapy. Preclinical studies with oral TP-317 in tumor models of these cancers have shown potent single-agent activity, and enhanced efficacy when combined with immune checkpoint inhibitors, chemotherapy and their combination.
Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration. The SBIR Award (R44CA278026) is supported by the National Institute of Cancer of the National Institutes of Health (NIH). Statements regarding TP-317 and the SBIR Award are solely the responsibility of Thetis Pharmaceuticals LLC and do not represent the official views of the NIH.
Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com